Effect of nucleolin on adriamycin resistance via the regulation of B‐cell lymphoma 2 expression in Burkitt's lymphoma cells

Nucleolin (NCL, C23) is an important nucleocytoplasmic multifunctional protein. Due to its multifaceted profile and high expression in cancer, NCL is considered to be a marker of drug resistance associated with chemotherapy. However, the biochemical mechanisms in which NCL suppresses drug sensitivity in several cancers have yet to be fully elucidated. This study aims to explore the effect of NCL on drug sensitivity and its potential mechanism in CA46 Burkitt's lymphoma (BL) cells. CA46 BL cells were transfected with lentiviruses carrying the NCL gene (CA46‐NCL‐overexpression, CA46‐NCL‐OE), or shRNA sequences that target the endogenous NCL gene (CA46‐NCL‐knockdown, CA46‐NCL‐KD). Adriamycin (ADM) IC50 levels for CA46‐NCL‐overexpressed (OE), CA46‐NCL‐OE control (OEC), CA46‐NCL‐knockdown (KD), and CA46‐NCL‐KD control (KDC) cells were 0.68 ± 0.06 μg/ml, 0.68 ± 0.06 μg/ml, 0.68 ± 0.06 μg/ml, and 0.30 ± 0.04 μg/ml, respectively. Apoptosis rates were significantly increased following NCL KD, whereas the opposite effect was noted in OE cells. A significant reduction of B‐cell lymphoma 2 (Bcl‐2) mRNA and protein levels in KD cells was observed, while OE cells displayed the opposite effect. The stability of Bcl‐2 mRNA was influenced by NCL levels, the half‐life of which was extended after NCL‐OE, whereas it was reduced in KD cells. Finally, results of RNA‐immunoprecipitation assays indicated that NCL could bind to Bcl‐2 mRNA in CA46 cells. Taken together, these results suggested that NCL could mediate Bcl‐2 expression and stability, and thus enhance ADM resistance in CA46 BL cells.

[1]  HSP90 Inhibitor , 2020, Definitions.

[2]  B. Kahl,et al.  Targeting BCL-2 in Hematologic Malignancies , 2018, Targeted Oncology.

[3]  T. Shamsi,et al.  Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy? , 2018, Cancer management and research.

[4]  R. Mathur,et al.  Targeting nucleolin for better survival in diffuse large B-cell lymphoma , 2018, Leukemia.

[5]  John Calvin Reed,et al.  Therapeutics targeting Bcl-2 in hematological malignancies. , 2017, The Biochemical journal.

[6]  Jiajun Zhao,et al.  New perspectives of physiological and pathological functions of nucleolin (NCL) , 2017, Life sciences.

[7]  A. Plesa,et al.  Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients , 2017, PloS one.

[8]  Gang Zhao,et al.  AS1411-Induced Growth Inhibition of Glioma Cells by Up-Regulation of p53 and Down-Regulation of Bcl-2 and Akt1 via Nucleolin , 2016, PloS one.

[9]  A. Janecka,et al.  ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy. , 2016, Current pharmaceutical design.

[10]  R. Christopherson,et al.  The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia , 2015, Oncotarget.

[11]  John Calvin Reed,et al.  Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. , 2015, Blood.

[12]  K. Kimura,et al.  CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population , 2014, Oncogene.

[13]  Xueting Liu,et al.  Nucleolin Down-Regulation Is Involved in ADP-Induced Cell Cycle Arrest in S Phase and Cell Apoptosis in Vascular Endothelial Cells , 2014, PloS one.

[14]  N. Shen,et al.  A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis , 2014, Oncotarget.

[15]  J. Said,et al.  Burkitt Lymphoma and MYC: What Else Is New? , 2014, Advances in anatomic pathology.

[16]  Jie-shi Zhang,et al.  RETRACTED ARTICLE: Nucleolin Promotes TGF-β Signaling Initiation via TGF-β Receptor I in Glioblastoma , 2014, Journal of Molecular Neuroscience.

[17]  M. Lipinski,et al.  Perinucleolar relocalization and nucleolin as crucial events in the transcriptional activation of key genes in mantle cell lymphoma. , 2014, Blood.

[18]  Jianda Hu,et al.  Knockdown of nucleophosmin by RNA interference reverses multidrug resistance in resistant leukemic HL-60 cells. , 2013, Immunobiology.

[19]  A. Sabichi,et al.  Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. , 2013, Blood.

[20]  Michael A. Freitas,et al.  In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation , 2013, The Journal of experimental medicine.

[21]  Yongzhang Luo,et al.  Prognostic Significance of the Combined Score of Endothelial Expression of Nucleolin and CD31 in Surgically Resected Non-Small Cell Lung Cancer , 2013, PloS one.

[22]  Jianda Hu,et al.  DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia. , 2011, Leukemia research.

[23]  J. Martinez-Climent,et al.  Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. , 2010, Blood.

[24]  C. Pepper,et al.  The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. , 2010, Leukemia research.

[25]  T. Sengupta,et al.  Mechanism of Regulation of bcl-2 mRNA by Nucleolin and A+U-rich Element-binding Factor 1 (AUF1)* , 2010, The Journal of Biological Chemistry.

[26]  Masashi Kato,et al.  Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice , 2010, BMC Cancer.

[27]  D. Schadendorf,et al.  The new face of nucleolin in human melanoma , 2009, Cancer Immunology, Immunotherapy.

[28]  E. M. Reyes-Reyes,et al.  Cell-surface nucleolin is a signal transducing P-selectin binding protein for human colon carcinoma cells. , 2008, Experimental cell research.

[29]  E. Spicer,et al.  The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. , 2008, Cancer research.

[30]  Tapas K Sengupta,et al.  Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. , 2007, Blood.

[31]  T. Sengupta,et al.  Retinoid-Induced Apoptosis in HL-60 Cells Is Associated with Nucleolin Down-Regulation and Destabilization of Bcl-2 mRNA , 2005, Molecular Pharmacology.

[32]  T. Sengupta,et al.  Identification of Nucleolin as an AU-rich Element Binding Protein Involved in bcl-2 mRNA Stabilization* , 2004, Journal of Biological Chemistry.

[33]  T. Sengupta,et al.  Taxol- and okadaic acid-induced destabilization of bcl-2 mRNA is associated with decreased binding of proteins to a bcl-2 instability element. , 2003, Biochemical pharmacology.

[34]  T. Haneji,et al.  Cleavage of nucleolin and argyrophilic nucleolar organizer region associated proteins in apoptosis-induced cells. , 2003, Biochemical and biophysical research communications.

[35]  J. Malter,et al.  Up-regulation of Nucleolin mRNA and Protein in Peripheral Blood Mononuclear Cells by Extracellular-regulated Kinase* , 2001, The Journal of Biological Chemistry.

[36]  T. Myers,et al.  An informatics approach identifying markers of chemosensitivity in human cancer cell lines. , 2000, Cancer research.

[37]  M. Mann,et al.  Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. , 2000, Genes & development.

[38]  H. Pollard,et al.  Molecular dissection of nucleolin's role in growth and cell proliferation: new insights , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  B. Dörken,et al.  Identification of Apoptosis-associated Proteins in a Human Burkitt Lymphoma Cell Line , 1998, The Journal of Biological Chemistry.

[40]  L. Foroni,et al.  Okadaic acid‐induced apoptosis of HL60 leukemia cells is preceded by destabilization of bcl‐2 mRNA and downregulation of bcl‐2 protein , 1998, FEBS letters.

[41]  V. Callea,et al.  Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs. , 1997, Haematologica.

[42]  M. Weller,et al.  Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. , 1995, The Journal of clinical investigation.